Oncology Licensing Deal Benchmarks 2026

The 2026 oncology licensing market continues to be driven by innovation in antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals, and cell therapies. Phase 2 ADC deals lead in total deal value at $2.6B median, while Phase 1 CAR-T transactions command $1.0B on the strength of clinical proof of concept in hematologic malignancies. Phase 3 small molecule deals average $3.1B with the highest upfront ratios.

Deal structures across oncology modalities share common patterns but diverge in key areas. ADC and bispecific deals are characterized by higher development milestone allocations due to manufacturing and formulation complexity. CAR-T and gene therapy deals feature longer milestone schedules reflecting extended development timelines. Small molecules and naked antibodies follow more traditional milestone structures.

Royalty rates in oncology licensing have stabilized in the 13.6%-22.2% range at the base tier for most modalities, with tiered escalation rewarding blockbuster commercial performance. The most competitive pressure on royalty rates comes from crowded IO-combination and kinase inhibitor spaces, while novel modalities with limited competition command premium rates.